IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 18, Issue 1 Ser. 11 (January. 2019), PP 45-55
www.iosrjournals.org

The Vital Role of Advanced Generation Anti-PSMA having Special CAR-T of PSMA in Cancer of Prostate having Immunotherapy Analysis.

Kifayat Ullah[1], Muhammad Asad Iqbal[3], Nida Fatima Moazzam[3], Feng Yu[2], Zhang yafi[4], HaiFeng Shi[2].

[1,2] Institute of life sciences, Jiangsu University, 301 Xuefu Road, Zhenjiang, Jiangsu, People's Republic of China, 212013

[3] School of Medicine of Jiangsu University, Zhenjiang, Jiangsu Province, China, 212013.

Corresponding Author: HaiFeng Shi

Abstracts: *CAR T cell therapy havean extraction from designed T cells (dTc) locomotive engineered of chimeric antigen receptors (CARs) for tumoricidal action correspond potency having elevation of specific role for the management of cancer. In this study, the first generation dTc are adapted with chimeric immunoglobulin T cell receptor while the second generation dTc are engineered with an immunoglobulin CD28 T cell receptor which integrated a CD28 costimulatory signal for optimal T cell stimulation. It determines the cognition of chimeric T cell receptors (CTR) load-bearing T cells to recognize humanlike prostate specific membrane antigen (hPSMA) on epithelium targets in both vitro and vivo. The CAR T cells are created using the anti-PSMA, and the intracellular signaling domains, CD3ζ and CD28. T cells supporting the third generation anti-hPSMA CAR, P28BBζ, were capable to recognize and kill off the primary human endothelial cell separate from gynecological carcinoma. While4thgeneration CAR having an extra unique feature by releasing cytokine transgene.Current review is focus on the 1st, 2nd, 3rd and 4thgeneration's antiprostate specific membrane antigen (PSMA) CARs and their applications for combating prostate carcinoma.*

Conclusions: *This research demonstrate that Ist ,2nd ,3rd and 4th generation of the anti-PSMA designer T cells exhibit superior antitumor function versus first generation, also providing the prostate cancer immunotherapy. CAR-T cell therapy is mainly achieved in the treatment of hematologic malignancies a breakthrough in the stage of its tumor research in the field has great potential value. But in the treatment of solid tumors is not mature, failed to produce excepted effect. By finding the appropriate tumor surface antigens, overcome tumor immunosuppressive microenvironment, optimization of co-stimulatory molecules, and construction. The fourth generation of Cars, design suicide gene, to reduce adverse reactions after reinfusion should be such as to enhance the anticancer activity of toxic, has become a hot research in this field.*

Keywords: *prostate specific antigen/therapeutic use/biosynthesis; receptors, Antigen, t- cell/therapeutic use; prostate Cancer/treatment reviews*

Date of Submission: 07-01-2019 Date of acceptance: 22-01-2019

I. Introduction

The 2016 Annual year, around 181,000 fresh causes of prostate carcinoma and Also round about deaths of 26,000 were calculated in the United States of America [1]. The patients of incoming with initial disease at designation, having the endurance of 5 years was about 28% from the annual year 2003 to 2009 [2]. The Androgen deprivation therapy (ADT) was usable for about one to three years, latterly increased with the causal agent of abiraterone & enza-lutamide [3, 4]. Fashionable the patients with castrate resistant prostate carcinoma (CRPC), additive profit were achieved with the chemotherapies such as docetaxel and cabazitaxel [5, 6]. Sipuleucel-T, and homologous "therapeutic vaccine," adds survival of the further months[7]. And no care was still verified alterative in metastatic settings.

The designer of interior "CAR" T cell (CAR-T, DTC) plan of attack was an invention versus of immunizing agent that are circumferential immunization, to unsure chance with the any self antigen and supply receptor of broad force by engineering [8]. Atypically, the sensory receptor (CARs) was primers of antibody binds with the domains of chains signaling to the T cell receptor (TCR). The interpretation was done for the scheme was antecedently incontestable inhibit and possibly treat the (CLL) [9, 10].and the document Scribe the first petitions of engineering science in prostate carcinoma.

Scientists have engineered the chimeric immunoreceptors to make anti-prostate specific membrane antigen and DTC which generally mark and also termination of prostate carcinoma in both vivo and vitro models [11].This was a first generation having zeta only artificial T cell receptors, and has geographical area in ontogenesis with interaction antigen conflicting to necrobiosis. AICD shows with antithetical first generation chimeric immunoreceptors, in dTcs see below which were exhortatory an improved therapeutically effect with this dTc factor.

Scientists and other researchers antecedently amuse the demand for interleukin 2 (IL2) linked to eliminate constituted tumors in the animal theoretical account exploitation first or second generation chimeric T cell receptors with full presentation of value of Interleukin 2 having TILs in human therapy (elaborated below further). Interleukin 2 concealed treated CD4 supporter T cells is an indispensable cytokines for endurance & enlargement T cells at one time treated, exclude the cytotoxic T cells CD8. The practice session, which steady of interleukin 2 concealed topically by helper T cells CD4 separate out the solid tumors which adopted medical care mostly inadequate for effecter T cells CD8 prolong toxicant consequence needful for riddance tumor. Thus, the cell medical cares for solid tumor atypically goodness for general interleukin 2 sub junction, within different scope of regimes invented and well-tried. Likewise, interleukin 2 was thinking to be critical to incorporated in our work in prostate carcinoma.

Medical institution of A phase I test were planned, and raise to endurance of the fuse Chimeric antigen receptors, Researchers make over a "hematopoietic space" with non-myeloablative chemotherapy ("conditioning") earlier extraction of T cell. The scheme showed off welfare with tumor-product leukocyte in malignant melanoma (TILs), efficaciously acceleratory patients "medicine vulnerability" and accrued no. of TILs [12]. An increase of T cell dose was conceived to attain a minimal 20 percent engraftment of fuse treated cell berth-bone marrow recovery. Decrease level medication interleukin2 (LDI) administrated to prolong stimulation of the fuse chimeric antigen receptors.The Prostate carcinoma is the almost average malignity in United States gender males and is the 2nd only to lung carcinoma as origin of casualties in men in the America. It's also important to create new & efficacious alternative mode for the patients with innovative metastasis sickness. Prostate specific membrane antigen (PSMA) also verbalized by selection of average prostate epithelial tissue and also increases levels in prostate carcinoma which accumulated farther in pathologic process trauma & endocrine intractable diseases. As PSMA also become a bewitching target for anti-prostate tumor target therapy. Researchers [13] & scientists [14–16] also formulated anti-PSMA T cells designed scheme into conflict prostate carcinoma.

The second decennary, native target therapy aside extract of T cells engineered with chimeric T cell receptors (CARs) of oriented tumoricidal inactiveness corresponds which possibly extremely circumstantial logical relation for the care of pathological process of carcinoma. chimeric immunoreceptors are manufacture while join the antigen identification domains the antibody in the signal domains of T cells from receptors . Alteration of CAR genes with T cells fit with retargeting antibody type anticancer toxicity. The violent death of MHC discretionary, the approachable offering a broad medical care for the entire patients load-bearing antigen identical. These engineered Tcells with artificial chimeric immunoreceptors called"designer T cells"(Dtc)"CAR-T cells," or "T-bodies" [17, 18].

A biological science T-lymphocyte consequences, optimum T-lymphocyte stimulation postulates the betrothal of 2 signals (1) The Antigen stimulation signal (Signal 1) which also presents via TCR-CD3 knotty and (2) The costimulatory signaling (Signal 2) which presents direct 1 or more costimulatory receptors, and foremost characterized the CD28 [19,20]. and The activation of the signal 1 in lack of the CD28 signal which consequence in the precise poor T-lymphocyte develop response and the initiation of energy or cell death [19, 20]. The CD28 is occupied from its natural substance, B7 is also existing on antigen-presenting cells, The CD28 increases stimulation consequence which is attach to stimulation of TCR, guiding the optimize of T-lymphocyte stimulation with the cytokine manufacturing &ontogenesis. The first generation chimeric antigen receptors, IgTCR are engineered to comprise the signal domain (TCR) that delivers a stimulation stimulant (Signal 1) only. However good appropriate for activation lysis roles [21,22], examination by scientists [23] and researchers [15,24,25] incontestable of betrothal the IgTCR wasn't enough to full actuate the adapted T-lymphocytes for essential IL2 escarpment and T cell ontogenesis also lack of the attendant costimulatory of signal.

One of the crucial and essential improvement in this heed has been the prosperous and buffo initiation of 2nd gen CARs, eg, immune serum globulin-CD28 T-lymphocyte sensory receptor (IgCD28TCR) also integrated the CD28 costimulatory signaling into the first generation receptor [15,25,26]. An IgCD28 TCR delivering the two signals 1 & 2 into adapted dTc constricting a singular neoplasm antigen. Actual the data demonstrates the below meeting with Antigen eliciting oncogenic cells, First generation dTc create small interleukin 2 & participate in cell death [15, 23, 24], while 2nd gen release significant assets of IL2 [15, 23, 24], participate exclusive elaboration [15], and expose increased antigen-particular victim cell convalescence [27]. It is farther incontestable that Although IgTCR and IgCD28 TCR converted T cell effecter aggregation exhibits

cell lysis of neoplasmic cells in vitro, T cells explicit the IgCD28 TCR chimera atypically has the greatest capability to stop the development of oncogenic cells in the vivo [28].



Fig. 1.Almost majority Cars are formulated of surface antigen-binding region, transmembrane region and intracellular signal transduction. From monoantibody derives the antigen-binding region of heavy (Hv) and light (VL) chains, which bear pliable by hinge area. Dimmer membrane proteins like CD3, CD8, and CD28 are found in transmembrane region. Intracellular signal transduction region is ascribed to immunor tyrosine-based activation motifs, involving CD3ζ or FcƐRlγ.

The carcinoma of prostate is the 2nd major origination of carcinoma associated deaths in United States gender men. [29,30] Also endocrinal secretion & therapy of radiation is very effectual in tropical diseases, The patients normally stubborn into medical hormonal care castration resistant within one to three years and these are commonly related to transformation of much bellicose form of the disease, guiding the improvement of the bone & body parts metastasis. and improver of collection chemotherapy in the early phases of the disease has moodiest beneficial, exploding endurance for various months.[31] almost stodgy care yet neglect, extra therapeutically schemes have been improved.[32] These medical care plan of actions have engaged oncolytic viruses,[33] vaccines,[34] auxiliary immune transmission medical aids checkpoint inhibitors and adoptive immune cell (T cell) therapies.[35] During the last 15 years, genetically engineering has been practical to much ineffectively direct T cells to tumor-expressed antigens, direct the aspect of specific chimeric T cell receptors (CARs) on an individual patient's T cells.[36,38] CARs exist of a tumor antigen constricting domain that is united to an extracellular signal domains and costimulatory receptors able of energizing T cells.[38,40] Hence, antigen identification is not MHC limited as is the cause for T cell receptor mediate antigen acceptance. In efficacy of *vivo* in CAR adapted effecter human and rodent T cells has been incontestable, [41-50] and prostate specific membrane antigen is an auspicious molecular marker for mark therapy of prostate carcinoma. PSMA is a type-II glycosylated membrane macromolecule that is organized during benign alteration is more assertive carcinoma of prostate, resultant in aberrant advanced plane of it on the cell subsurface[51]. We [52,53] and others [49,54,57] have taken part in underdeveloped construction of chimeric T cell receptors to attain much intense personal effects in the target area of tumor load-bearing the comparable antigen human PSMA. Chimeric immunoreceptors in tumors solid has not win the medical trails successfulness that has been ascertained in hematological malignity [58-60]. One Intellect for the wretched handling consequence is the no achievement of CAR T cells to collect & thrive in the antagonistic tumor micro geographic region.[61,62]

According to the United States Cancer Society (ACS) in late 2014, analysis of prostate cancer (prostate cancer, PCa) about tumor 27%, far higher than other cancer, has become the European American males the highest incidence of cancer [63]. PCa in the Early androgen-dependent characteristics of hormone therapy to achieve a better effect, but the majority of patients are after these endocrine treatment will eventually develop into castration resistant prostate cancer (CRPC) and will gradually become metastatic castrate resistant prostate cancer (mCRPC) having no effective treatment for old [64] .Cellular immunotherapy for the treatment of tumors and also provide a new way diameter. Therefore adoptive T cell therapy techniques have been attention, for using CAR-T cell adoptive immunotherapy targeted therapies are swollen in which most representative and

widespread attention by scholars at home and abroad in recent years. In August 2011, Porter, old [65]. Applications such as targeting antigen of CD19 CAR-T Cells for the treatment of chronic lymphocytic leukemia patients with successful recover from dissolved syndrome tumor (Tumor Lysis Syndrome) in rehabilitation. The blood and bone marrow has been no evidence of leukemia. The tumor residual after six months follow-up, the review of the evidence, showing that CAR-T has a very good prospect in the malignant tumor.



Fig. 2. The Chimeric antigen receptors in 1st generationhaving single antibody chain connected to ITAM (CD24ζ OR FcƐRlγ) region of transmambrane. The 2nd generation, constimulatory molecules (CMI like CD28) is engineered to the transduction region signal. and the 3rd generation has been another constimulatory molecule (CM2) based on the 2nd generation, combining CD137 OR CD134. The 4th generation Car having extra unique feature by releasing cytokine transgene

1. T- leucocytes-mediated tumor devastation performance:

The T-lymphocytes-mediated immune response is also known as cell-mediated immune response. Tumor cell antigens was first APCs processing, presenting, and in antigenic peptide-MHC Class I complexes are expressed on the cell surface, and these are for specific CD8+T cell surface recognition [66]. T-Cell having specific binding with the APCs and by CD3 molecules to intracellular specific antigen stimulation signal, which improve its stability and extend the time of T-cells and APCs results, and this is due to effective induction of the role of T-cells and cytokines [67]. One of the first signal for specificity, by which identify the antigen presenting cell surface antigen peptide-MHC complexes are started; The second signal is for coordinating stimulus signal, through which the important common stimulation such as CD28/B7 and other important common Co-stimulatory molecules, promote the synthesis of IL-2 and full activation of T-cells adequately and from apoptosis [68]. Be activated CD8+T cells rapidly cloning, amplification, and further differentiation into effected T cells which reach the specific antigen assemble their parts, and biological effect started into full play. The current research showed that CTL can kill cancer cells into two main ways (1)The release of perforin /granzyme cells, and doxorubicin-mediated apoptosis in target cells, after that CTL FasL expression model and two effects of soluble FasL, and effectors molecules such as secretion of TNF-a,Lta, including apoptosis in target cells. [69].

2. PSMA Specific chimeric Antigen receptors of T cells (CAR-T) Handling schemes:

2.1. Project of CAR-T Therapy:

In recent years, with the rapid development of genetic engineering technology, application artifact antigen receptor (chimeric Antigen receptor, CAR study of T cell killing of tumor cells is rapidly show state of the old [70] . The CAR-T cells, has been bloated by recognition tumor-associated antigens (tumor associated antigen, TAA) and intracellular signaling domains "immune receptor tyrosine based activation motif (ITA CD3 ∈ or FceRI) "in vitro recombinant plasmid [71] And then by transfection in vitro transected to patient T cell I

antigen receptors of T cells in patients with tumor, after transfection. Hence After purification and large-scale expansion of T cells, These CARs are known as chimeric antigen receptors of T cells (CAR-T cell) [72]. CAR-T cells have been developed over three generations of CARs[73]. CAR by extra cellular antigen-binding domain, Trans membrane and intracellular signaling (ITAM) [74]. In 1989, this year Eshhar [75, 76], Immunoglobulin-like receptor scFv and FceRI (Complex (∈ chain) CD3 by intracellular domain fused to form chimeric receptors and synthesis the first generation of CARs. The CD3 ∈ chain of CA for more clinical research because CD3 containing three ITAMs effect of activated T cells to tumor elimination capacity [68, 77]. The second generation and third generation CARs are based on the dual of T-cell activation signal in the chimeric receptors and costimulatory molecules (gesticulatory Molecule, GM) such as CD28, CDl3 (41BB) [78]. The second generation of intracellular signal CAR CMl Costimulatory molecules, mainly for the CD28 molecule, CAR introduced a pair of costimulatory molecules (CMl and CM2 CD28 molecule with CDl34 0*40 or CDl37 [17]. Cytotoxicity, proliferation activity, the maintenance of T cell responses to extend T cell survival time.

2.2 The Prostate Specific Membrane Antigen (PSMA):

The PSMA is present in a prostate epithelial cell membrane of an intrinsic membrane protein, gene mapping in 1lpll~12 [79]. Contains 750 amino acids and a molecular weight of 100 Kd structure for the short period of cell I (amino acids 1-18), Trans membrane segments (ammonia 19 ~ 43) and long extra cellular domain (amino acids 44 - 750 [80]. Skoloff [79] A sensitive application of double-antibody sandwich Elisa quantitative analysis and spectrometry, found high expression in prostatic tissues PSMA, Nests and low expression of the cell membrane of the breast, colon, liver, kidney and other membrane no expression, PSMA in semen content, Therefore, specific high expression in prostate epithelial cells. Because of the PSMA membrane-bound and prostate tissue specificity, in the PCa, the special CRPC is over expressed. PCa immune targeted therapy in egg white.



Fig. 3. Minicircular DNA nanophase system is a general vector of gene therapy, with a superiority of DNA delivery. It targets different diseases by changing the DNA sequence with the preservation of the basic structure. The CAR-T technique could be optimized by transfection of the T cells via nanophase-minicircle DNA.

2. 3. Targets of CAR T in PSMA malignancy

The PSMA as a target of CAR-T cell therapy Zuccolotto [79]. To establish a PSMA T-treated rat model of PCa, anti-h PSMA D2B miscellaneous Anti-h PSMA scFv complete genetic sequence obtained in tumor cells, Long into the pSecTa92A plasmid cloning site CD3' chain and introducing CD28 Costimulatory molecules to form a recombinant antihuman PSMA chimeric T cell receptors from healthy donors, Through the

transfection technology recombinant plasmid transfected into T-cells, purification and amplification takes place, and access to CAR-T cells. In nod/scid mice shooting fluorescent PC3 PIP tumor cells established prostate cancer animal models, 4d, mice were randomly divided into the experimental group and the control group. After 72h injection of Chimeric antigen receptors T cells in the lesions with experimental group, but there was nothing in control group, the tumor size and overall survival in rats (overall Survival, OS) were evaluated. Results: ① experimental mice Injection of CAR-T decreases the tumor cells after 1 week, 3 weeks the tumor disappeared, but tumors in the control group continued to grow, it becomes larger in volume; @CAR-T cells can improve survival. Os group mice out extended, with a statistically significant difference that CAR-T cells enough to inhibit the growth of prostate cancer cells and improve the Os. [80] Made with old u embedded CD28 Costimulatory molecules such as anti PSMA and CAR-T cells and therapeutic effect of first generation contrast. Retroviruses as carriers, made healthy T cells from Anti-PSMA IgTCR CAR-T cell of the first generation and second generation anti-PSMA IgCD28TCR CAR-T cells. Make the following The two groups: ① a PSMA PC3 prostate tumor cell lines 96-well plate with $5*10^4$ cell/cellular culture, the average 3, 51Cr radiation 4H radiation markers, respectively, one general cell, anti-PSMA IgTCR CAR-T, anti- IgCD28TCR CAR-T, training 4H. From 3 kinds of micro-hole cell activation and cytotoxicity,(2) Male BALB/c-n Nude mice were randomly divided into 3 groups, each group of 8, subcutaneous injection of PC3 p MA in prostate cancer cells, and injected the same day general T-cells, anti-PSMA IgTCR CAR-T、anti-IgCD28TCR CAR-T, regular monitoring of tumor size, and so on. Test results showed: ①Ordinary T cells, anti-PSMA IgTCR CAR-T anti-PSMA IgCD28TCR CAR-T 3 in porous media, T-cell activation and cytotoxicity of progressive state, Anti-PSMA IgCD28TCR CAR-T was significantly higher than in the previous two tumor size in 5th day after inoculation of the first peak, General through T-cell group is gently reduced tumor size, again long anti-PSMA IgTCR CAR-T tumor size in peak significantly decreased steadily since to continue increasing; anti- PSMA IgCD28TCR CAR-T tumors significantly decreased after peak. A week after the tumor has all but disappeared, normal T-cell anti-PSMA IgTCR CAR-T and anti PSMA IgCD28TCR CAR-T there was a significant statistical difference between them. Whether in vitro or animal solid test on prostate cancer cells and CAR-T cells has shown significant killing effect of clinical targeting therapy of CRPC provides the basis.

1. Advantages:

CAR-T has versatile and benignant nature to cure cancer.

Vision with the PSMA as a target of CAR-T cell therapy in *vitro*.Animal experiments have made an important progress, CAR T related signaling pathway needs to be further explored. CAR-T cell for only one type of target antigens before the next ability to multi-targeting CAR, also for PSA, PSMA, PSCA, and other types of target antigens which improve immune therapy specificity and decrease of tumor immune escape and ultimatelyoffers a new toolto prostate cancer treatment. However put aside all the social factors, researcher's first priority is to improve CAR-T therapy all can make hope to cure cancer.

CAR-T therapy achilles has two A: first could trigger "cytokines Storms "B: the second is specific antigens are hard to find it. The former used by IL 6 receptor resistances tocilizumab can be controlled cancer specific antigen on the surface. Researchers have to wait until the foundation research found the "new world", and then show specific CAR T, let the decades asked thousands of patients die? For this scientists need to look again into the immune checkpoints in signaling mechanism to explore possible to improve the program.

Second and third generation CAR T coactivation molecules, not free antigen on total suppression of the disease free focus check. Envisaged in the tumor cells and is expression of cell surface antigen A and only in normal expression of cell surface antigen B. If another strategy is to double the signal balancing machine requires activation of CAR signal A receptor expression. If the antigens A and B are expressed on the surface of tumor cells, without at the same time expressed on the surface of normal cells, through A and B receptor activated T cells while only A or B receptor activation not T cell activation "5". In addition, the increase in vitro transformation T fine cell efficiency is also very important. Choosing efficient, Cellular toxicity and be able to point integration base making T cells express both identify A CAR and identify B iCAR. Only when CAR and ligand are combined with activated T-cells, then CAR and iCAR concerted with ligand iCAR inhibitory signal which artifact the effects of CARs and can be improve the efficiency of CARs too. The specificity of iCAR is expected to play a role in fighting solid tumors. Dang vectors, transfection of T-cell survival rates and transform CAR so that it can high expression in the cells and improve the CAR itself qualitative would be CAR -T, this technology needs aspect.

***1. Disadvantages*:**

CAR-T is not on top and still inadequate in many aspects:

The author will present the main tumor treatment list therapies were compared as can be seen in CAR T. Although with less trauma to the patient treatment of week advantages are shorter, but not perfect as a form of CAR T therapy. Therefore sex is a big problem needs attention. Current three generations of CAR T two-year

clinical trials time but if it can cure cancer, and then there is no conclusion on the current CAR T view, this therapy remains inadequate in many offices. Starting with the CAR T principles involved considered, due to the CAR T cells express tumor antigen is a direct recognition and has a total signaling domain of the receptor is activated, it skips the immune checkpoint restrictions, probably to normal cells cause undesired damages or missing effects and tumor specific antigen still know very little, which limits CAR-T of clinical applications. In 2010, researchers used ERBB target's third-generation CAR T treat a colon cancer patients with lung and liver metastases, 10^{10} Cell infusion of 1 5min, a lot of CAR T tired deposition in the lung, attack low expression of ERBB2 lung epithelial cells and the release of cytokines, the risk symptoms of pulmonary edema occurs, died 5 days later.

The current CAR-T therapy in the CDl9 for the target antigen of B-cell malignant tumor blood cancer has made exciting knots fruit, but in the treatment of solid tumors have not curative effect. Back in 2006, the global CAR T clinical trials are for entities currently 15 CAR T treatment of entities most of the clinical studies was the first generation CAR-T. However, due to solid tumor immunity micro-environment immune cells easily into real body tumors, as well as eliminating needed for solid tumors number of T-cells than blood cancer treatment need CAR T technology for solid tumors treatment is still a long way to go.

Secondly, from the CAR T cells of the whole Process considerations, gene carriers primarily for transfer viral vectors with high efficiency, such as reverse transcriptase HIV carriers (including Lent viral vectors), adenovirus carrier and adeno associated virus (AAV) vector integration of adeno-associated virus in the human genome points can be redirected to a chromosome 19th AA Points, The two other types of viral vectors are not ability to integrate specific sites, which may lead caused by insertional mutagenesis of the gene, or by inserting reset in the control region of a gene causing the base due to changes in expression level and, thus, cannot be predict the consequences. T cells in vitro genetic modification will cause apoptosis of T cells after transfection, gene cannot express. Reports showed that the removal CD3[2 ITAM domain are kept to apoptosis cells after transfected 31, but 1 ITA the limited capacity of T-cell activation, so before upgrading is still expressed in T cells with 3 ITAM domain CD3[CAR. However, such then CAR rates will also decrease. By to filter the CAR. T stable plant is one of the giant project, after that still needs a lot of expansion additional CAR. On t-billions of baiyige long back to input the patient's body to produce significant the clinical effect. This process can be described as "road ahead is long ". Furthermore, from the CAR.T clinical treatment of stage to consider a lot of CARs. T cells into the patient's body, combined with relevant antigens are activated and will produce excess of cytokines, leading to fine cell cytokine release syndrome (CRs), Resulting in a high symptoms such as tachycardia, severe cases can lead to death. For example, in 2014 by United States Sloan Kettering Cancer Center led to a CAR. T in the treatment of non-Hodgkin's lymphoma period due to trigger a "cytokine storm" And cause of death. However, there are some clinical experiences; use IL 16 antibody tocilizumab should be effectively controlled.

Finally, cancer immunotherapy is suitable objects considered as a cancer autoimmune diseases, or need to use the immune inhibition of drug patients, but such patients in the patient population is not the most. In addition, medical or not do not take into account the social problems. CAR-T therapy a major weakness is the high cost of curative effect and other drugs in the context of competitive advantage it’s not obvious. Immune cells in cancer therapy from patient isolation of T cells in vivo and in *vitro* outside of GM and a lot of amplification, these therapies can actually be seen as genetic cure therapies. Therefore, the CAR. T treatments are extremely expensive, Treatment of 300,000 for ~50 million Yuan, far beyond the average family's commitment to force. So, from the perspective of costs, for some diseases, such as the Philadelphia chromosome-positive acute lymphocyte leukemia, CAR. T-therapy than small molecular targeted therapeutic drugs and there is no significant advantage.

II. Discussion

It's necessary that T lymphocyte is in the active state to expose its toxin purpose. Best T cell stimulation necessitates the betrothal of signal one and two. and the vantage of the 2nd generation Chimeric antigen receptors, IgCD28 TCR, over the first generation IgTCR is that it delivers both signal one & two arrange together through one receptor molecule. It also furnishes the second generation DTc with superior T cell activation upon neoplasm contact. Hence consequences intelligibly incontestable that upon connection with PSMA-expressing cancer cells, the second generation anti-PSMA DTc can be excited to create considerably larger quantity of interleukin 2 & IFNg and to uncontrollable growth at speeded up rate, while conserving cytotoxic potential strength. The mostly dandy impressive goodness of the second generation DTc over the first generation DTc in our endeavors and it is super tumoricidal active in vivo.

The Sadelain and its coworkers antecedently improved DTc consist on anti-PSMA antibody J591. IL2 production and specific ontogenesis growth on PSMA-expressing neoplasm link &in vitro maintained toxicity for PSMA-expressing tumor cells and super anti-PSMA therapeutically inefficacy in the model of animal.

The Modern trials of clinical have been demonstrated the affectivity of Chimeric antigen receptors T cell-supported target therapy of single person with precocious malignant neoplastic diseases. Noteworthy the responses have examined, eg, in patients getting CD19 specific chimeric antigen receptors T-cell therapy of curing the CLL. A captious constituent to the clinical developing adventure of these adoptive chimeric antigen receptors T-cell therapies is the selection of mark antigen. The Antigen should be immunologic, connected to oncological diseases, and by selection it showed on the neoplasmic tissue. The tumorveins are PSMA marker, whose far-flung commotion on blood veins of many benign makes it a perfect target area for T cell-mediated vascular commotion. and it shows that T cells containing a chimeric antigen receptors against PSMA can ruin the tumor vasculature and arouse neoplasm retrogression. Significantly, this data also shows that T cells can perform activity as powerful intermediator of vascular disruption, therefore, confirming the continuation of research about this therapeutic conceptualization. first prima benefit of using Chimeric antigen receptors T cells to interrupt the cancer in both musculature and vasculature, as defy to accept VDAs, is their capability to self-duplicate and to continue prolong-term in patients. Besides, chimeric antigen receptors T cells can actuate epitope scattering and help to reset the tumor microenvironment. Bestowed the continuity and affectivity Chimeric antigen receptors T cells, a second captious constituent to the clinical prosperity of Chimeric antigen receptors T-cell therapy is to provide safe environment. They cannot be exaggerated, as an unannounced CAR cross-sensitivity with firm tissues has unluckily, cells or create "Hemopoietic Space" ability in the *vivo* ontogeny and engraftment of the transfer cells.

PSMA countenance is reported on the vasculature of closely in solid tumor kind is examined. The intimated is proximity and impression it can be crucial to the arrangement of fresh blood vessels within the tumor. and here we found that the 85 percent of mature females with carcinoma of ovary uttered PSMA on their neoplasm vasculature but just 40–60% of the $CD31^{+}$ tumor epithelium cells were $PSMA^{+}$.In finales, it has been proved that 3rd generation Chimeric antigen receptors T cells can mark and destruct PSMA-explicating epithelial tissues of the tumor vasculature both as well as *in vitro &vivo*, and evacuation of these cells can consequence in tumor retrogression. It declare that disconnected-signaling may improve their protection and security outline, and that, in accumulation with handling i.e. chemotherapy, radiation, and tumor cell targeting T cells, they deliver essential and necessary clinical goodness to patients.

References

[1]. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7–30.

[2]. American Cancer Society. Prostate cancer, special section in cancer facts & figures 2010. Atlanta GA: American Cancer Society; 2010. pp. 23–37.

[3]. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995–1905.

[4]. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investi-gators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187–1197.

[5]. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242–245.

[6]. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A ran-domised open-label trial. Lancet 2005; 376:1147–1154.

[7]. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators. Sipuleu-cel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2008; 363:411–422.

[8]. Ma Q, Gonzalo-Daganzo RM, Junghans RP. Genetically engi-neered T cells as adoptive immunotherapy of cancer. Cancer Chemother Biol Response Modif 2002; 20:315–341.

[9]. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725–733.

[10]. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73.

[11]. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Jungans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 2004; 61:12–25.

[12]. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Fillie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy follow-ing non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346–2357.

[13]. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 2004; 61:12–25.

[14]. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999; 1:123–127.

[15]. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002; 20:70–75.

[16]. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M.Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31:71–75.
[17]. Ma Q, Gonzalo-Daganzo RM, Junghans RP. Genetically engi-neered T cells as adoptive immunotherapy of cancer. Cancer Chemother Biol Response Modif 2002; 20:315–341.
[18]. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011; 29:550– 557.
[19]. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co stimulates murine T cells and prevents induction of energy in T-cell clones. Nature 1992; 356: 607–609.
[20]. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimula-tion: A review. Crit Rev Immunol 1998; 18:389–418.
[21]. Geiger TL, Leitenberg D, Flavell RA. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. JImmunol 1999; 162:5931–5939.
[22]. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ, Darcy PK. Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs. Fc epsilon RI-gamma. J Immunol 2001; 166:182–187.
[23]. Beecham EJ, Ma Q, Ripley R, Junghans RP. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: The dynamics of T-cell proliferation and death. J Immunother 2000; 23:631–642.
[24]. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, baken H.T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect recep-tor-mediated target cell lysis. Cancer Res 2001; 61:1976–1982.
[25]. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001; 167:6123–6131.
[26]. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998; 161: 2791–2797.
[27]. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004; 172:104– 113.
[28]. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002;169: 5780–5786
[29]. Hsing, A.W., Tsao, L., and Devesa, S.S. (2000). International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 85, 60–67.
[30]. Siegel, R.L., Miller, K.D., and Jemal, A. (2015). Cancer statistics, 2015. CA Cancer J.Clin. 65, 5–29.
[31]. Ning, Y.M., Gulley, J.L., Arlen, P.M., Woo, S., Steinberg, S.M., Wright, J.J., Parnes,H.L., Trepel, J.B., Lee, M.J., Kim, Y.S., et al. (2010). Phase II trial of bevacizumab,thalidomide, docetaxel, and prednisone in patients with metastatic castration-resis-tant prostate cancer. J. Clin. Oncol. 28, 2070–2076
[32]. Clarke, J.M., and Armstrong, A.J. (2013). Novel therapies for the treatment ofadvanced prostate cancer. Curr. Treat. Options Oncol. 14, 109–126.
[33]. DiPaola, R.S., Plante, M., Kaufman, H., Petrylak, D.P., Israeli, R., Lattime, E., Manson,K., and Schuetz, T. (2006). A phase I trial of pox PSA vaccines (PROSTVAC-VF) withB7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients withprostate cancer. J. Transl. Med. 4, 1.
[34]. Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F.,Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., et al. (2010). Sipuleucel-T immu-notherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422.
[35]. Hillerdal, V., and Essand, M. (2015). Chimeric antigen receptor-engineered T cells forthe treatment of metastatic prostate cancer. BioDrugs 29, 75–89.
[36]. Sadelain, M., Rivière, I., and Brentjens, R. (2003). Targeting tumors with geneticallyenhanced T lymphocytes. Nat. Rev. Cancer 3, 35–45.
[37]. Sadelain, M. (2009). T-cell engineering for cancer immunotherapy. Cancer J. 15,451–455.
[38]. Morello, A., Sadelain, M., and Adusumilli, P.S. (2016). Mesothelin-targeted CARs:driving T cells to solid tumors. Cancer Discov. 6, 133–146.
[39]. Geiger, T.L., and Jyothi, M.D. (2001). Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. Transfus. Med. Rev. 15,21–34.
[40]. Ma, Q., Gonzalo-Daganzo, R.M., and Junghans, R.P. (2002). Genetically engineeredT cells as adoptive immunotherapy of cancer. Cancer Chemother. Biol. ResponseModif. 20, 315–341.
[41]. Altenschmidt, U., Klundt, E., and Groner, B. (1997). Adoptive transfer of in vitro-tar-geted, activated T lymphocytes results in total tumor regression. J. Immunol. 159,5509–5515.
[42]. Darcy, P.K., Haynes, N.M., Snook, M.B., Trapani, J.A., Cerruti, L., Jane, S.M., andSmyth, M.J. (2000). Redirected perforin-dependent lysis of colon carcinoma byex vivo genetically engineered CTL. J. Immunol. 164, 3705–3712.
[43]. Haynes, N.M., Trapani, J.A., Teng, M.W., Jackson, J.T., Cerruti, L., Jane, S.M.,Kershaw, M.H., Smyth, M.J., and Darcy, P.K. (2002). Single-chain antigen recogni-tion receptors that costimulate potent rejection of established experimental tumors.Blood 100, 3155–3163.
[44]. McGuinness, R.P., Ge, Y., Patel, S.D., Kashmiri, S.V., Lee, H.S., Hand, P.H., Schlom, J.,Finer, M.H., and McArthur, J.G. (1999). Anti-tumor activity of human T cells ex- pressing the CC49-zeta chimeric immune receptor. Hum. Gene Ther. 10, 165–173.
[45]. Hwu, P., Yang, J.C., Cowherd, R., Treisman, J., Shafer, G.E., Eshhar, Z., andRosenberg, S.A. (1995). In vivo antitumor activity of T cells redirected with chimericantibody/T-cell receptor genes. Cancer Res. 55, 3369–3373.
[46]. Wang, G., Chopra, R.K., Royal, R.E., Yang, J.C., Rosenberg, S.A., and Hwu, P. (1998).A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing ahuman ovarian cancer antigen. Nat. Med. 4, 168–172
[47]. Chekmasova, A.A., Rao, T.D., Nikhamin, Y., Park, K.J., Levine, D.A., Spriggs, D.R.,and Brentjens, R.J. (2010). Successful eradication of established peritoneal ovarian tu-mors in SCID-Beige mice following adoptive transfer of T cells genetically targeted tothe MUC16 antigen. Clin. Cancer Res. 16, 3594–3606.
[48]. Brentjens, R.J., Latouche, J.B., Santos, E., Marti, F., Gong, M.C., Lyddane, C., King,P.D., Larson, S., Weiss, M., Rivière, I., and Sadelain, M. (2003). Eradication of sys-temic B-cell tumors by genetically targeted human T lymphocytes co-stimulated byCD80 and interleukin-15. Nat. Med. 9, 279–286
[49]. Gade, T.P., Hassen, W., Santos, E., Gunset, G., Saudemont, A., Gong, M.C., Brentjens,R., Zhong, X.S., Stephan, M., Stefanski, J., et al. (2005). Targeted elimination of pros-tate cancer by genetically directed human T lymphocytes. Cancer Res. 65, 9080–9088.

[50]. Adusumilli, P.S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D.R., and Sadelain, M. (2014). Regional delivery of mesothelin-targeted CART cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Sci. Transl. Med. 6, 261ra151.

[51]. Sweat, S.D., Pacelli, A., Murphy, G.P., and Bostwick, D.G. (1998). Prostate-specificmembrane antigen expression is greatest in prostate adenocarcinoma and lymphnodemetastases. Urology 52, 637–640.

[52]. Dobrenkov, K., Olszewska, M., Likar, Y., Shenker, L., Gunset, G., Cai, S., Pillarsetty,N., Hricak, H., Sadelain, M., and Ponomarev, V. (2008). Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PETand bioluminescence imaging. J Nucl Med. 49, 1162–1170

[53]. Likar, Y., Dobrenkov, K., Olszewska, M., Shenker, L., Cai, S., Hricak, H., andPonomarev, V. (2009). PET imaging of HSV1-tk mutants with acquired specificity toward pyrimidine- and acycloguanosine-based radiotracers. Eur. J. Nucl. Med.Mol. Imaging 36, 1273–1282

[54]. Baiz, D., Hassan, S., Choi, Y.A., Flores, A., Karpova, Y., Yancey, D., Pullikuth, A., Sui, G., Sadelain, M., Debinski, W., and Kulik, G. (2013). Combination of the PI3K inhib-itor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regres-sion of prostate cancer. Neoplasia 15, 1172–1183

[55]. Gong, M.C., Chang, S.S., Sadelain, M., Bander, N.H., and Heston, W.D. (1999). Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 18, 483–490

[56]. Gong, M.C., Latouche, J.B., Krause, A., Heston, W.D., Bander, N.H., and Sadelain, M.(1999). Cancer patient T cells genetically targeted to prostate-specific membraneantigen specifically lyse prostate cancer cells and release cytokines in response to prostate specific membrane antigen. Neoplasia 1, 123–127

[57]. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S.,Stefanski, J., Taylor, C., Olszewska, M., et al. (2013). CD19-targeted T cells rapidly lymphoblastic.

[58]. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S.,Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci. Transl. Med. 6, 224ra25.

[59]. Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X.,James, S.E., Raubitschek, A., Forman, S.J., et al. (2008). Adoptive immunotherapy formodified.

[60]. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., Huls, M.H.,Liu, E., Gee, A.P., Mei, Z., et al. (2008). Virus-specific T cells engineered to coexpresstumor-specific receptors: persistence and antitumor activity in individuals with neu-roblastoma. Nat. Med. 14, 1264–1270.

[61]. Peres, E., Wood, G.W., Poulik, J., Baynes, R., Sood, S., Abidi, M.H., Klein, J.,Bhambhani, K., Dansey, R., and Abella, E. (2008). High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.Neuropediatrics 39, 151–156

[62]. Santoro s，Kim s，Motz G，et a1.T cells bearing a chimeric antigen receptor against prostate specific membrane antigen mediate vascular disruption and result in tumor regression [J]．Cancer immunology research，2014．

[63]. Sanchez C，Chan R，Bajgain P，et a1．Combining T- cell immunotherapy and antiandrogen therapy for prostate cancer [J].Prostate cancer and prostatic diseases，2013, 16 (2)：123--131

[64]. Porter DL，Levine BL，Kalos M，et a1．Chimeric antigen receptor modified T cells in chronic lymphoid leukemia [J]．N Engl JMed，2011,365 (8)：725-733.

[65]. Duong CP，Westwood JA，Berry LJ，et a1．Enhancing the specificity of T cell cultures for adoptive immunotherapy of cancer [J].immunotherapy，2011, 3 (1)：33-48．

[66]. Li z，Chen L，Rubinstein MP．Cancer immunotherapy: are we there yet [J]．Experimental hematology＆oncology 2013, 2 (1): 33．

[67]. Ramos CA，Dotti G．Chimeric antigen receptor (CAR)engineered lymphocytes for cancer therapy [J]．Expert opinion on biological therapy，2011，11 (7)：855 -873．

[68]. Aseierto PA，Addeo R，Carteni G，et a1．The role of immunotherapy in solid tumors report from the Campania Society of Oncology Immunotherapy(SCITO)meeting，Naples 2014[J]．Jour of translational medicine，2014,12 (1)：291．

[69]. Kloss CC，Condomines M，Cartellieri M，et a1．Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered Tcells [J].Nat Biotechnol，20 13, 31 (1)：71 75．

[70]. Hillerdal V，Ramachandran M，Leja J，et a1．Systemic treatment with CAR—engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice [J]．BMC cancer，2014，14：30．

[71]. Lipowska-Bhalla G，Gilham DE，Hawkins RE，et a1．Target immunotherapy of cancer with CAR Tcells：achievements and challenges [J]．Cancer immunologyimmunotherapy 61 (7)：953-962．

[72]. Anurathapan U，Chan RC，Hindi HF，et a1．Kinetics of tumor destruction by chimeric antigen receptor—modified T cells [J]. Molecular therapythe journal of the American Society of Gene Therapy，2014，22 (3)：623-633．

[73]. Abate-Daga D，Lagisetty KH，Tran E，et a1．A Novel Chimeric Antigen Receptor against Prostate Stem Cell Antigen Mediate Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer [J] ．Human gene therapy，2014，25 (12)：1003-1012.

[74]. Eshhar Z，Waks T，Gross G，et a1．Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the immunoglobulin and T cell receptors [J]．Proceedings of the National Academy of Sciences of the United States of America 1993，90 (2)：720-724．

[75]. Gross G，Waks T，Eshhar Expression of immunoglobulin T- cell receptor chimeric molecules as functional receptors with anti-body type specificity [J]．Proceedings of the National Academy of Sciences of the United States of America，1989，86 (24):0024-10028．

[76]. Katari UL，Keirnan JM，Worth AC，et a1．Engineered T cells for pancreatic cancer treatment [J]．HPB：the official journal of the International Hepato Pancreato Biliary Association，2011 ，13 (9)：643-650．

[77]. Park TS，Rosenberg SA，Morgan RA．Treating cancer with genetically engineered T cells [J]．Trends in biotechnology，201 1，29 (11)：550-557．

[78]. Maher J，Brentjens RJ，Gunset G，et a1．Human T—lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRze— ta / CD28 receptor [J]．Nature biotechnology，2002, 20 (1):70-75．

[79]. Zuccolotto G，Fracasso G，Merlo A，et a1．PSMAspecific CAR engineered T cells eradicate disseminated prostate cancer in pre-clinical models [J]．PloS one，2014, 9 (10)：e109427.
[80]. Kloss CC，Condomines M，Cartellieri M，et a1．Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells [J]．Nature biotechnology， 2013，31(1)：71-75.
[81]. Sokoloff RL，Norton KC，Gasior CL，et a1．A dualmonoclonal sandwich assay for prostate specific membrane antigen: levels in tissues，seminal fluid and urine [J]．The Prostate，2000，43 (2)：150-157
[82]. Ma Q，Gomes EM，Lo AS，et a1．Advanced generation antiprostate specific membrane antigen designer T cells for prostate cancer immunotherapy [J]．The Prostate，2014，74 (3) 286-296.

HaiFeng Shi. “The Vital Role of Advanced Generation Anti-PSMA having Special CAR-T of PSMA in Cancer of Prostate having Immunotherapy Analysis.” IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), vol. 18, no. 1, 2019, pp 45-55.